Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 14,400 shares, an increase of 82.3% from the March 15th total of 7,900 shares. Based on an average trading volume of 1,050,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.7% of the company’s stock are short sold.

Pasithea Therapeutics Price Performance

Shares of NASDAQ KTTA traded up $0.01 during midday trading on Friday, hitting $1.38. 113,976 shares of the company’s stock were exchanged, compared to its average volume of 967,266. The firm’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $2.53. The company has a market cap of $3.73 million, a PE ratio of -0.11 and a beta of 0.59. Pasithea Therapeutics has a twelve month low of $0.92 and a twelve month high of $7.69.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($2.41) earnings per share for the quarter.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.